Breaking Finance News

Infinity Pharmaceutical (NASDAQ:INFI) has been upgraded from Market Perform to Outperform in a statement by Wells Fargo earlier today.

Wells Fargo has upgraded Infinity Pharmaceutical (NASDAQ:INFI) from Market Perform to Outperform in a statement released on 10/12/2017.

Having a price of $1.67, Infinity Pharmaceutical (NASDAQ:INFI) traded 57.57% higher on the day. With the last close up 60.51% from the two hundred day average, compared with the Standard & Poor's 500 Index which has increased 0.03% over the same period. INFI has recorded a 50-day average of $1.20 and a two hundred day average of $1.64. Trade Volume was up over the average, with 23,326,234 shares of INFI changing hands over the typical 963,074

Recent Performance Chart

Infinity Pharmaceutical (NASDAQ:INFI)

Infinity Pharmaceutical has with a one year low of $0.84 and a one year high of $3.84 and has a market capitalization of $0.

A total of 8 analysts have released a report on Infinity Pharmaceutical. Four analysts rating the company a strong buy, four analysts rating the company a buy, one analyst rating the company a hold, zero analysts rating the company a underperform, and finally zero analysts rating the company a sell with a 12-month price target of $13.50.

General Company Details For Infinity Pharmaceutical (NASDAQ:INFI)

Infinity Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is engaged in the discovery, development and delivery of medicines to treat diseases. The Company develops small molecule drugs that target disease pathways for potential applications in oncology. Its product candidate is duvelisib, also known as IPI-145, is an oral, dual-inhibitor of the delta and gamma isoforms of phosphoinositide-3-kinase (PI3K), for the treatment of hematologic malignancies, or blood cancers. The Company is also developing IPI-549, which is an orally administered, clinical-stage, immuno-oncology product candidate that selectively inhibits the gamma isoform of PI3K. In addition to duvelisib, the Company focuses to generate new product candidates for potential investigation in oncology. The Company also focuses on developing DYNAMO, CONTEMPO, BRAVURA, FRESCO, DYNAMO+R, DUO, SYNCHRONY and Duvelisib + Venetoclax.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.